INT295474

Context Info Confidence 0.18 First Reported 2010 Last Reported 2010 Negated 1 Speculated 0 Reported most in Body Documents 1 Total Number 1 Disease Relevance 0.41 Pain Relevance 0.03

cytoplasm (IRF6, MAP2K1) cytosol (IRF6, MAP2K1) nucleus (IRF6, MAP2K1) mitochondrion (MAP2K1) Golgi apparatus (MAP2K1) DNA binding (IRF6)

Anatomy Link Frequency adipocytes 1 IRF6 (Homo sapiens) MAP2K1 (Homo sapiens)

Pain Link Frequency Relevance Heat Inflammation 15 57.60 cytokine 2 5.00 Kinase C inhibitor 1 5.00 Kinase C 1 5.00 anesthesia 1 5.00

Disease Link Frequency Relevance Heat Obesity 68 99.48 INFLAMMATION 15 57.60 Diabetes Mellitus 2 5.00 Metabolic Syndrome 2 5.00 Insulin Resistance 1 5.00 Necrosis 1 5.00 Overweight 1 5.00 Cancer 1 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Chelerythrine alone does not modify the effect of LPS on TNFalpha, which in a way would seem logical, since PKC activates MEK1/2 classically; whilst LPS does not activate MEK1/2 in mature adipocytes.

LPS Neg (not) Positive_regulation (activate) of MEK1 in adipocytes associated with obesity

1) Confidence 0.18 Published 2010 Journal J Inflamm (Lond) Section Body Doc Link PMC2819999 Disease Relevance 0.41 Pain Relevance 0.03

General Comments

This test has worked.